Related Experiment Video
Updated: Aug 13, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Pharmacoenhancement of protease inhibitors
1Division of Infectious Diseases, Department of Internal Medicine, FUHS/The Chicago Medical School, Chicago, Illinois 60064, USA.
Abstract:
Toxicity, adherence problems, and virological failure may limit treatment by protease inhibitor-containing regimens at standard doses. Addition of low-dose ritonavir results in a high plasma concentration of coadministered protease inhibitor resulting in decreased pill burden, a reduction in the number of doses, fewer food and/or fluid restrictions, and a higher rate of virological suppression. These effects are due to improved pharmacokinetics of coadministered protease inhibitors.
Related Concept Videos
Pharmacokinetics: Drug–Drug Interactions
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
Drug toxicity: Drug–Drug Interaction

